The Ministry of Health will finance two drugs, marketed under the names Enhertu and Trodelvy, to treat metastatic breast cancer, after the approval this Thursday of the Interministerial Price Commission after several failures, sources present at the meeting confirm to elDiario .
The organization has refused three times for the public system to assume the high cost of these drugs, according to a group of patients who have been mobilizing since the summer to demand government funding. A 21-day cycle costs 5,500 euros.
Pressure from patients in recent weeks has been decisive in the change of position. Three of them – Victoria Rodrigo, Rosa Olmos and Raquel Campoy – conveyed their message two days ago to senators through the campaign “Without drugs we die” and associated the refusal to finance the two drugs with reasons economic and lack of agreement. to the marketing company.
The Secretary of State for Health, Javier Padilla, predicted that he would bring the approval of drugs back to the Commission last week and assured that his team has always supported the financing in a committee including the Treasury, Economy, Industry and autonomous communities.
Enhertu was already authorized in Spain for “other indications,” as Padilla explains, so “it could be used for special use by autonomous communities.” From now on, this procedure will no longer be necessary to access it.
